share_log

Aditxt | 8-K: Current report

Aditxt | 8-K: Current report

Aditxt | 8-K：重大事件
美股SEC公告 ·  10/31 04:19

Moomoo AI 已提取核心訊息

On October 28, 2024, Aditxt, Inc., a Delaware-based biotech company, entered into a significant agreement with Evofem Biosciences, Inc., purchasing 2,280 shares of Evofem Series F-1 Convertible Preferred Stock for $2,280,000. This transaction was accompanied by a Registration Rights Agreement, ensuring Evofem would file a registration statement for the resale of common stock issuable upon conversion of the preferred stock. The event also featured a fireside chat with Aditxt's CEO, Amro Albanna, and Evofem's CEO, Saundra Pelletier, moderated by Dr. Drew Pinsky. The discussion highlighted Aditxt's commitment to women's health, showcasing products like Phexxi®, a hormone-free contraceptive, and SOLOSEC®, a treatment for bacterial vaginosis and trichomoniasis. The conversation also touched on the potential for early detection of conditions like endometriosis through Aditxt's subsidiary, Pearsanta. The acquisition of Evofem by Aditxt is still in progress, pending the satisfaction of closing conditions, including the resolution of a senior loan.
On October 28, 2024, Aditxt, Inc., a Delaware-based biotech company, entered into a significant agreement with Evofem Biosciences, Inc., purchasing 2,280 shares of Evofem Series F-1 Convertible Preferred Stock for $2,280,000. This transaction was accompanied by a Registration Rights Agreement, ensuring Evofem would file a registration statement for the resale of common stock issuable upon conversion of the preferred stock. The event also featured a fireside chat with Aditxt's CEO, Amro Albanna, and Evofem's CEO, Saundra Pelletier, moderated by Dr. Drew Pinsky. The discussion highlighted Aditxt's commitment to women's health, showcasing products like Phexxi®, a hormone-free contraceptive, and SOLOSEC®, a treatment for bacterial vaginosis and trichomoniasis. The conversation also touched on the potential for early detection of conditions like endometriosis through Aditxt's subsidiary, Pearsanta. The acquisition of Evofem by Aditxt is still in progress, pending the satisfaction of closing conditions, including the resolution of a senior loan.
2024年10月28日，總部位於特拉華州的生物科技公司aditxt與evofem biosciences達成重要協議，購買了evofem系列f-1可轉換優先股2280股，總價爲228萬美元。這筆交易附帶註冊權協議，確保evofem會爲可轉換優先股轉換後可發行的普通股提交註冊聲明。該活動還舉辦了一個由drew pinsky博士主持的aditxt首席執行官amro albanna和evofem首席執行官saundra pelletier的爐邊聊天。討論突出了aditxt對婦女健康的承諾，展示了phexxi®，一種無激素避孕藥，以及solosec®，一種治療細菌性陰道病和滴蟲陰道病的產品。談話還涉及通過aditxt子公司pearsanta對病症如子宮內膜異位症的早期檢測潛力。aditxt收購evofem的交易仍在進行中，還需滿足結束條件，包括解決高級貸款問題。
2024年10月28日，總部位於特拉華州的生物科技公司aditxt與evofem biosciences達成重要協議，購買了evofem系列f-1可轉換優先股2280股，總價爲228萬美元。這筆交易附帶註冊權協議，確保evofem會爲可轉換優先股轉換後可發行的普通股提交註冊聲明。該活動還舉辦了一個由drew pinsky博士主持的aditxt首席執行官amro albanna和evofem首席執行官saundra pelletier的爐邊聊天。討論突出了aditxt對婦女健康的承諾，展示了phexxi®，一種無激素避孕藥，以及solosec®，一種治療細菌性陰道病和滴蟲陰道病的產品。談話還涉及通過aditxt子公司pearsanta對病症如子宮內膜異位症的早期檢測潛力。aditxt收購evofem的交易仍在進行中，還需滿足結束條件，包括解決高級貸款問題。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間